Tests AZD0901 in advanced cancers that express Claudin 18.2

Other criteria

• The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria
• Master Inclusion Criteria applicable to all sub studies:
• Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF
• Participants who are CLDN18.2 positive
• Must have at least one measurable lesion according to RECIST v1.1
• ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing
• Predicted life expectancy of ≥ 12 weeks
• Adequate organ and bone marrow function as defined by protocol
• Body weight > 35 kg
• Participants are willing to comply with contraception requirements; Sub study 1 Specific Inclusion criteria:
• Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction
• Advanced or metastatic GC/GEJC
• Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease; Sub study 2 Specific Inclusion criteria:
• Participants diagnosed with histologically confirmed metastatic or advanced PDAC
• Availability of an archival sample or a fresh tumour biopsy taken at screening
• No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed ≥ 6 months (183 days) from the last dose; Sub study 3 Specific Inclusion criteria
• Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible)
• Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease; Master Exclusion Criteria applicable to all sub studies:
• Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy
• Participants with clinically significant ascites that require drainage
• A history of drug-induced non-infectious ILD/pneumonitis
• Central nervous system metastases or CNS pathology
• Peripheral neuropathy, sensory, or motor ≥ Grade 2 at screening
• History of another primary malignancy
• Prior exposure to any MMAE-based ADC
• Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody; Sub study 1 Specific Exclusion criteria:
• Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available
• Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
• The use of concomitant medications known to prolong the QT/QTc interval; Sub study 2 Specific Exclusion criteria:
• Known DPD enzyme deficiency based on local testing where testing is SoC
• Use of strong inhibitor or inducer of UGT1A1
• Use of strong inhibitors or inducers of CYP3A4
• Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC; Sub study 3 Specific Exclusion criteria
• Clinically significant biliary obstruction that has not resolved before enrollment